Business Context and Reporting Period
This Form 8-K was filed by LabStyle Innovations Corp. (referred to in metadata as Dariohealth Corp.) on November 19, 2015. The report details the closing of a private placement offering on the same date. The Company is developing Dario, a mobile, cloud-based diabetes management solution combining software with a pocket-sized blood glucose monitoring device.
Key Financial Metrics
- Total Proceeds: Approximately $2.3 million.
- Units Sold: 7,648,267 Units.
- Purchase Price: $0.30 per Unit.
- Capital Structure Impact: Issuance of 7,648,267 shares of Common Stock and Warrants exercisable for an aggregate of 7,648,267 additional shares.
- Use of Proceeds: Funding global penetration and the initial U.S. commercial launch of the Dario product, plus working capital.
Material Changes and Transaction Details
The Company entered into a definitive securities purchase agreement with existing shareholders and private investors. Each Unit consists of one share of Common Stock and two warrants:
- Series A Warrant: Purchases 0.7 shares at $0.37/share; exercisable immediately; expires in 16 months.
- Series B Warrant: Purchases 0.3 shares at $0.43/share; exercisable immediately; expires in 36 months.
In connection with the Offering, the Company agreed to issue finders 823,097 restricted shares of Common Stock and corresponding Finders' Warrants with terms identical to the Series A and Series B Warrants described above.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected use of proceeds for the U.S. commercial launch. The Company cautions that actual results may differ materially due to risks discussed in other SEC filings. The securities issued are exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, as the transaction involved accredited investors and was not a public offering. These securities may not be sold in the United States absent registration or an exemption.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess dilution impact.
- Confirm the status of the U.S. commercial launch timeline for the Dario product.
- Review the Company's cash runway relative to the $2.3 million raised to determine future funding needs.
- Check for any subsequent filings regarding the registration of the Warrants for resale.